SilTerra Malaysia, a semiconductor company, has embarked on its transformation towards developing cutting edge health technology.
Ranked by IC Insight, an established industry analyst, as the top 16th global semiconductor focused company, the company sees potential in the life sciences market which is expected to reach $25.60 billion by 2023 with a CAGR of 15.3%.
“This is an important aspect of our overall strategy to improve the quality of our revenue stream,” says Firdaus Abdullah, currently SilTerra’s Chief Executive Officer (CEO) who has been instrumental in leading the company into profitability since his tenure in 2015.
In addition, SilTerra is actively developing nano-scaled biosensors that can be incorporated into IOT (Internet of Things) and POC (point-of-care) devices. The devices will allow direct access to detect and diagnose diseases such as dengue, malaria and cancer without having to wait for lengthy lab results, bringing groundbreaking efficiencies to the forefront of healthcare delivery.
SilTerra Kickstarts Ecosystem to Support Technologies in HealthcareOrganizes first-in-Asia Semiconductors in Life Sciences Symposium, Penang
SilTerra attributes much of its recent innovation to its existing partnership with imec, the world’s leading research and innovation hub in nanoelectronics and digital technologies.
In line with its commitment towards this direction, SilTerra, supported by the renowned imec, has taken the lead in the region by kickstarting an ecosystem towards the development of technologies in healthcare by organising a first-in-Asia Semiconductors in Life Sciences Symposium, which took place recently in Penang, Malaysia.